# A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

> **NCT05263869** · PHASE2 · UNKNOWN · sponsor: **Shanghai Miracogen Inc.** · enrollment: 99 (estimated)

## Conditions studied

- Breast Cancer With Liver Metastases

## Interventions

- **DRUG:** MRG002

## Key facts

- **NCT ID:** NCT05263869
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-23
- **Primary completion:** 2022-12
- **Final completion:** 2023-10
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263869, "A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05263869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*